Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | FURIN | P09958 | 4/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149172 | 0.89 | FURIN (0.49) | HTTSMN1; SMN2FURINCRHBPCRHR2 | |
| SCHEMBL24393476 | 0.87 | FURIN (0.40) | HTTSMN1; SMN2FURINLMNASIRT1 | |
| SCHEMBL25124339 | 0.86 | FURIN (0.43) | HTTSMN1; SMN2FURINSIRT1L3MBTL1 | |
| SCHEMBL25655950 | 0.85 | FURIN (0.41) | HTTSMN1; SMN2FURINSIRT1 | |
| SCHEMBL16769624 | 0.85 | FURIN (0.41) | HTTSMN1; SMN2FURINSIRT1 | |
| SCHEMBL24220963 | 0.84 | SIRT2 (0.41) | HTTSMN1; SMN2FURINSIRT1 | |
| SCHEMBL20126461 | 0.84 | SIRT2 (0.41) | HTTSMN1; SMN2FURINLMNASIRT1 | |
| SCHEMBL18822243 | 0.84 | SIRT2 (0.41) | HTTSMN1; SMN2FURINSIRT1 | |
| SCHEMBL21728798 | 0.84 | SIRT2 (0.41) | HTTSMN1; SMN2FURINSIRT1 | |
| SCHEMBL22268356 | 0.83 | SIRT2 (0.44) | HTTFURINSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780935-B2 | Mutant antibodies and conjugation thereof | PFIZER HEALTHCARE IRELAND (IE) | 2023-10-10 | — | — | US | disclosed |
| US-20210147576-A1 | MUTANT ANTIBODIES AND CONJUGATION THEREOF | PFIZER HEALTHCARE IRELAND (IE) | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147576-A1 | MUTANT ANTIBODIES AND CONJUGATION THEREOF | IGLV6-57, IGSF11, F13B | KIF11 1727/4885EPHX1 944/4885HTT 2532/4885 |
| US-11780935-B2 | Mutant antibodies and conjugation thereof | IGLV6-57, IGSF11, F13B | KIF11 1700/4885EPHX1 944/4885HTT 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.